From the other SOX on the other board: Good job.

From the other SOX on the other board: Good job.

Kevetrin

- Orphan drug designation for K-ovarian cancer
http://cellceutix.com/cellceutixs-kevetrin-re...U1TnV.dpbs

- Orphan drug designation for K-pancreatic cancer
http://cellceutix.com/cellceutix-receives-fda...ZiRj0.dpbs

- Orphan drug designation for K-retinoblastoma
http://cellceutix.com/cellceutix-receives-fda...NePSd.dpbs

- Rare pediatric disease designation for K-retinoblastoma
http://cellceutix.com/cellceutix-receives-rar...jI8sG.dpbs

- Positive primary endpoint (Phase 1)
http://cellceutix.com/cellceutix-prepares-pha...Ur7N7.dpbs

Brilacidin

- QIDP designation for B-ABSSSI
http://cellceutix.com/cellceutix-antibiotic-b...vWGbq.dpbs

- Fast track designation for B-OM
http://cellceutix.com/fda-grants-fast-track-d...pFvLG.dpbs

- B-ABSSSI positive top-line & bottom line data (Phase 2b)
http://cellceutix.com/cellceutix-announces-po...LBVb3.dpbs

- American Society for Microbiology journal publication
http://aac.asm.org/content/early/2014/06/11/A...#corresp-1

- MTA extension for testing in implanted devices
http://cellceutix.com/cellceutix-completes-la...iYemt.dpbs

- Formulation stable at room temperature
http://cellceutix.com/cellceutix-announces-br...Zuqak.dpbs

Prurisol

- Positive top-line data (Phase 2a)
http://cellceutix.com/cellceutix-phase-2-tria...e9gTP.dpbs

- Positive primary endpoint (Phase 1)
http://cellceutix.com/cellceutix-anti-psorias...aMllD.dpbs

- 505(b)(2) pathway
http://cellceutix.com/cellceutix-informed-by-...BHEyW.dpbs

Clinical Trials

1. P (Phase 1, completed)
https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1

2. P (Phase 2, completed)
https://clinicaltrials.gov/ct2/show/NCT021012...amp;rank=2

3. B-OM (Phase 2, recruiting)
https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3

4. B-ABSSSI (Phase 2, completed)
https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=4

5. K (Phase 1, completed)
https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=5

6. B-UP (Phase 2 POC, recruiting)
http://cellceutix.com/cellceutix-receives-upd...5eSu9.dpbs